{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sirukumab", "query": { "intervention": "Sirukumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sirukumab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T00:38:57.285Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01856309", "title": "Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Sirukumab 100 mg", "type": "DRUG" }, { "name": "Sirukumab 50 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1820, "start_date": "2013-08-07", "completion_date": "2018-04-30", "has_results": true, "last_update_posted_date": "2019-05-06", "last_synced_at": "2026-09-03T00:38:57.285Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01856309" }, { "nct_id": "NCT01604343", "title": "A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Sirukumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1670, "start_date": "2012-08-15", "completion_date": "2016-12-06", "has_results": true, "last_update_posted_date": "2018-01-11", "last_synced_at": "2026-09-03T00:38:57.285Z", "location_count": 48, "location_summary": "Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 45 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01604343" }, { "nct_id": "NCT01606761", "title": "A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Sirukumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 878, "start_date": "2012-08-06", "completion_date": "2016-01-12", "has_results": true, "last_update_posted_date": "2018-03-23", "last_synced_at": "2026-09-03T00:38:57.285Z", "location_count": 81, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 78 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01606761" }, { "nct_id": "NCT04380961", "title": "A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Critical Confirmed Coronavirus Disease (COVID)-19" ], "interventions": [ { "name": "Sirukumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care (SOC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Pharmaceutica N.V., Belgium", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 212, "start_date": "2020-04-24", "completion_date": "2021-06-24", "has_results": true, "last_update_posted_date": "2022-06-21", "last_synced_at": "2026-09-03T00:38:57.285Z", "location_count": 16, "location_summary": "Long Beach, California • Newport Beach, California • Fort Lauderdale, Florida + 13 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04380961" }, { "nct_id": "NCT02473289", "title": "An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "Sirukumab 50 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "21 Years to 64 Years" }, "enrollment_count": 193, "start_date": "2015-07-23", "completion_date": "2018-05-22", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-03T00:38:57.285Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Lemon Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02473289" }, { "nct_id": "NCT01273389", "title": "An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "CNTO 136", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 25, "start_date": "2011-08", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2016-03-24", "last_synced_at": "2026-09-03T00:38:57.285Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Success", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01273389" }, { "nct_id": "NCT00718718", "title": "A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "CNTO 136 100 mg", "type": "DRUG" }, { "name": "CNTO 136 50 mg", "type": "DRUG" }, { "name": "CNTO 136 25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 187, "start_date": "2008-08-11", "completion_date": "2011-03-03", "has_results": true, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-09-03T00:38:57.285Z", "location_count": 8, "location_summary": "Aventura, Florida • Lexington, Kentucky • Frederick, Maryland + 5 more", "locations": [ { "city": "Aventura", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Frederick", "state": "Maryland" }, { "city": "Kalamazoo", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00718718" }, { "nct_id": "NCT02794519", "title": "A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Sirukumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2016-09-23", "completion_date": "2016-10-04", "has_results": false, "last_update_posted_date": "2018-08-31", "last_synced_at": "2026-09-03T00:38:57.285Z", "location_count": 5, "location_summary": "Long Beach, California • Aventura, Florida • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Richmond", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02794519" }, { "nct_id": "NCT02531633", "title": "Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Giant Cell Arteritis" ], "interventions": [ { "name": "Sirukumab", "type": "DRUG" }, { "name": "Placebo to match sirukumab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo to match prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 161, "start_date": "2015-10-16", "completion_date": "2018-03-21", "has_results": true, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-09-03T00:38:57.285Z", "location_count": 13, "location_summary": "Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Naples", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02531633" }, { "nct_id": "NCT02019472", "title": "A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "adalimumab 40 mg", "type": "BIOLOGICAL" }, { "name": "sirukumab 100 mg", "type": "BIOLOGICAL" }, { "name": "sirukumab 50 mg", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 559, "start_date": "2014-04-04", "completion_date": "2016-08-17", "has_results": true, "last_update_posted_date": "2017-10-26", "last_synced_at": "2026-09-03T00:38:57.285Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Arvin, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Arvin", "state": "California" }, { "city": "El Cajon", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02019472" } ] }